Cyntellect Receives $2.2 Million Milestone Payment From Sigma-Aldrich
News Jun 09, 2006
The milestone payment represents Cyntellect's satisfaction of certain terms and conditions under the two companies' exclusive Cell Xpress™ service commercialization agreement executed one year ago.
Sigma-Aldrich will employ Cyntellect's LEAP™ system to support its Cell Xpress service business to identify and clone high-producing cells used in manufacturing of biopharmaceuticals (such as recombinant proteins and monoclonal antibodies) and diagnostic antibodies.
"We are pleased to have achieved the next level in our relationship with Sigma-Aldrich, and we look forward to supporting their success in globally commercializing Cell Xpress," stated Fred Koller, Ph.D., President and Chief Technology Officer of Cyntellect.
Cell Xpress is based upon Cyntellect's proprietary LEAP (Laser Enabled Analysis and Processing) platform, which is designed to enable a high-throughput process for in situ measurement of protein secretion on an individual cell basis, coupled with laser-based elimination of undesired cells.
As a result, Cell Xpress directly clones the cells secreting the highest amounts of protein.
The automated capabilities of LEAP also provide for further process improvements by facilitating the integration of culture media optimization with the cell cloning process, in addition to detailed documentation about the clonal and growth history of each cell line that is developed to comply with FDA requirements.
Broadly Acting Antibodies Found in Blood of Ebola SurvivorsNews
Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness.READ MORE
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE